Dynavax Technologies Corporation (0IDA.L)
USD 12.91
(-0.26%)
USD 12.91
(-0.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.38 Million USD | -102.18% |
| 2022 | 293.15 Million USD | 282.15% |
| 2021 | 76.71 Million USD | 183.59% |
| 2020 | -91.77 Million USD | 39.38% |
| 2019 | -151.39 Million USD | 4.72% |
| 2018 | -158.89 Million USD | -66.99% |
| 2017 | -95.15 Million USD | 15.38% |
| 2016 | -112.44 Million USD | -5.29% |
| 2015 | -106.79 Million USD | -17.72% |
| 2014 | -90.72 Million USD | -35.97% |
| 2013 | -66.72 Million USD | 4.62% |
| 2012 | -69.94 Million USD | -43.94% |
| 2011 | -48.59 Million USD | 15.2% |
| 2010 | -57.3 Million USD | -87.5% |
| 2009 | -30.56 Million USD | -46.74% |
| 2008 | -20.82 Million USD | 65.27% |
| 2007 | -59.97 Million USD | -15.21% |
| 2006 | -52.05 Million USD | -153.23% |
| 2005 | -20.55 Million USD | -28.7% |
| 2004 | -15.97 Million USD | 7.96% |
| 2003 | -17.35 Million USD | 3.8% |
| 2002 | -18.03 Million USD | 2.03% |
| 2001 | -18.41 Million USD | 31.1% |
| 2000 | -26.72 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 11.38 Million USD | 230.56% |
| 2024 Q1 | -8.72 Million USD | -4082.19% |
| 2023 Q4 | 219 Thousand USD | -98.47% |
| 2023 Q3 | 14.29 Million USD | 316.58% |
| 2023 Q2 | 3.43 Million USD | 114.1% |
| 2023 Q1 | -24.33 Million USD | -135.92% |
| 2023 FY | -6.38 Million USD | -102.18% |
| 2022 FY | 293.15 Million USD | 282.15% |
| 2022 Q4 | 67.73 Million USD | 6.15% |
| 2022 Q1 | 32.72 Million USD | -67.2% |
| 2022 Q2 | 128.75 Million USD | 293.41% |
| 2022 Q3 | 63.8 Million USD | -50.44% |
| 2021 Q4 | 99.77 Million USD | 450.96% |
| 2021 Q1 | 821 Thousand USD | 105.31% |
| 2021 Q2 | 4.14 Million USD | 404.26% |
| 2021 Q3 | -28.43 Million USD | -786.71% |
| 2021 FY | 76.71 Million USD | 183.59% |
| 2020 Q4 | -15.46 Million USD | -451.44% |
| 2020 FY | -91.77 Million USD | 39.38% |
| 2020 Q3 | 4.4 Million USD | 108.53% |
| 2020 Q1 | -12.59 Million USD | 65.73% |
| 2020 Q2 | -51.57 Million USD | -309.52% |
| 2019 Q2 | -42.71 Million USD | -7.67% |
| 2019 FY | -151.39 Million USD | 4.72% |
| 2019 Q1 | -39.67 Million USD | 0.74% |
| 2019 Q3 | -33.45 Million USD | 21.67% |
| 2019 Q4 | -36.75 Million USD | -9.85% |
| 2018 Q3 | -40.52 Million USD | -2.75% |
| 2018 FY | -158.89 Million USD | -66.99% |
| 2018 Q4 | -39.96 Million USD | 1.38% |
| 2018 Q1 | -38.95 Million USD | -42.07% |
| 2018 Q2 | -39.44 Million USD | -1.25% |
| 2017 Q4 | -27.42 Million USD | -23.92% |
| 2017 Q2 | -20.31 Million USD | 19.65% |
| 2017 Q3 | -22.12 Million USD | -8.91% |
| 2017 Q1 | -25.28 Million USD | -16.31% |
| 2017 FY | -95.15 Million USD | 15.38% |
| 2016 Q4 | -21.74 Million USD | 37.33% |
| 2016 Q2 | -28.98 Million USD | -7.26% |
| 2016 Q1 | -27.02 Million USD | -0.6% |
| 2016 FY | -112.44 Million USD | -5.29% |
| 2016 Q3 | -34.69 Million USD | -19.69% |
| 2015 Q4 | -26.86 Million USD | 10.83% |
| 2015 Q3 | -30.12 Million USD | -27.69% |
| 2015 FY | -106.79 Million USD | -17.72% |
| 2015 Q2 | -23.59 Million USD | 10.02% |
| 2015 Q1 | -26.21 Million USD | -17.64% |
| 2014 Q1 | -13.84 Million USD | -6.0% |
| 2014 FY | -90.72 Million USD | -35.97% |
| 2014 Q2 | -24.77 Million USD | -79.02% |
| 2014 Q4 | -22.28 Million USD | 25.26% |
| 2014 Q3 | -29.81 Million USD | -20.35% |
| 2013 Q2 | -17.16 Million USD | 17.58% |
| 2013 Q4 | -13.05 Million USD | 16.71% |
| 2013 FY | -66.72 Million USD | 4.62% |
| 2013 Q3 | -15.67 Million USD | 8.68% |
| 2013 Q1 | -20.82 Million USD | -1.37% |
| 2012 FY | -69.94 Million USD | -43.94% |
| 2012 Q1 | -16.5 Million USD | -286.81% |
| 2012 Q2 | -15.11 Million USD | 8.45% |
| 2012 Q3 | -17.79 Million USD | -17.74% |
| 2012 Q4 | -20.54 Million USD | -15.47% |
| 2011 Q4 | -4.26 Million USD | 71.98% |
| 2011 Q3 | -15.22 Million USD | -43.2% |
| 2011 Q2 | -10.63 Million USD | 42.41% |
| 2011 Q1 | -18.46 Million USD | -22.11% |
| 2011 FY | -48.59 Million USD | 15.2% |
| 2010 Q2 | -28 Million USD | -204.92% |
| 2010 FY | -57.3 Million USD | -87.5% |
| 2010 Q4 | -15.12 Million USD | -202.56% |
| 2010 Q3 | -4.99 Million USD | 82.15% |
| 2010 Q1 | -9.18 Million USD | 69.66% |
| 2009 FY | -30.56 Million USD | -46.74% |
| 2009 Q1 | 5.1 Million USD | 64.6% |
| 2009 Q2 | 4.11 Million USD | -19.43% |
| 2009 Q3 | -9.5 Million USD | -331.29% |
| 2009 Q4 | -30.27 Million USD | -218.43% |
| 2008 FY | -20.82 Million USD | 65.27% |
| 2008 Q4 | 3.09 Million USD | 157.18% |
| 2008 Q3 | -5.42 Million USD | 10.84% |
| 2008 Q2 | -6.07 Million USD | 51.09% |
| 2008 Q1 | -12.42 Million USD | -2.92% |
| 2007 Q2 | -17.7 Million USD | -35.25% |
| 2007 Q1 | -13.09 Million USD | 20.45% |
| 2007 Q3 | -17.1 Million USD | 3.41% |
| 2007 Q4 | -12.07 Million USD | 29.38% |
| 2007 FY | -59.97 Million USD | -15.21% |
| 2006 Q4 | -16.45 Million USD | -35.41% |
| 2006 FY | -52.05 Million USD | -153.23% |
| 2006 Q1 | -8.17 Million USD | 6.73% |
| 2006 Q3 | -12.15 Million USD | 20.43% |
| 2006 Q2 | -15.27 Million USD | -86.89% |
| 2005 Q1 | 5.07 Million USD | 198.2% |
| 2005 FY | -20.55 Million USD | -28.7% |
| 2005 Q4 | -8.76 Million USD | -5.77% |
| 2005 Q3 | -8.28 Million USD | 3.44% |
| 2005 Q2 | -8.57 Million USD | -269.21% |
| 2004 Q4 | -5.16 Million USD | -28.02% |
| 2004 FY | -15.97 Million USD | 7.96% |
| 2004 Q3 | -4.03 Million USD | -38.64% |
| 2004 Q2 | -2.9 Million USD | 24.75% |
| 2004 Q1 | -3.86 Million USD | 14.85% |
| 2003 FY | -17.35 Million USD | 3.8% |
| 2003 Q4 | -4.54 Million USD | -9.69% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q2 | -3.95 Million USD | 16.17% |
| 2003 Q3 | -4.13 Million USD | -4.65% |
| 2002 FY | -18.03 Million USD | 2.03% |
| 2001 FY | -18.41 Million USD | 31.1% |
| 2000 FY | -26.72 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 95.83% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 585.486% |
| Perrigo Company plc | -12.7 Million USD | 49.693% |
| Illumina, Inc. | -1.16 Billion USD | 99.45% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.107% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.561% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.926% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 100.47% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 94.221% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.162% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 83.971% |
| Waters Corporation | 642.23 Million USD | 100.995% |
| Biogen Inc. | 1.16 Billion USD | 100.55% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.522% |
| Evolus, Inc. | -61.68 Million USD | 89.643% |
| Adicet Bio, Inc. | -142.65 Million USD | 95.521% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 94.609% |
| bluebird bio, Inc. | -211.91 Million USD | 96.985% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.947% |
| FibroGen, Inc. | -284.23 Million USD | 97.752% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 100.515% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 85.676% |
| Homology Medicines, Inc. | -53.74 Million USD | 88.112% |
| Geron Corporation | -184.12 Million USD | 96.53% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.549% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 95.785% |
| Myriad Genetics, Inc. | -112 Million USD | 94.296% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 92.562% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.672% |
| Zoetis Inc. | 2.34 Billion USD | 100.273% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 88.21% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 100.81% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 103.811% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.177% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 84.86% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 98.256% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.686% |
| Verastem, Inc. | -87.36 Million USD | 92.687% |
| Nektar Therapeutics | -276.05 Million USD | 97.686% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 97.329% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 92.779% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.808% |
| OPKO Health, Inc. | -188.86 Million USD | 96.617% |
| Exelixis, Inc. | 207.76 Million USD | 103.075% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 102.559% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 106.019% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 86.551% |
| uniQure N.V. | -308.47 Million USD | 97.929% |
| Imunon, Inc. | -19.51 Million USD | 67.261% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.74% |
| Insmed Incorporated | -749.56 Million USD | 99.148% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 102.269% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 98.185% |
| TG Therapeutics, Inc. | 12.67 Million USD | 150.418% |
| Incyte Corporation | 597.59 Million USD | 101.069% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 99.16% |